Phi Pharma intracellular targeting technology expands anti-cancer treatment options by targeting hitherto unaddressed cancer antigens expressed by a range of solid and liquid tumors. Initial Phi Pharma targeting peptides have been optimised for cell specific binding and high-capacity delivery of cytotoxic payloads. These properties allow increased drug concentration inside targeted cells while sparing off-target cell side-effects. Peptide-drug conjugates are designed for improved pharmacokinetic properties and uncoupling of the drug inside the target cells.